Work

SNMMI Consensus Statement on Patient Selection and Appropriate Use of 177 Lu-PSMA-617 Radionuclide Therapy

Year: 2023

Type: article

Abstract: Prostate-specific membrane antigen (PSMA) is a transmembrane carboxypeptidase that is highly expressed in prostate cancer. Radioligand therapy (RLT) with 177Lu-labeled compounds has shown clinical benefit, and the U.S. Food and Drug Administration (FDA) approved 177Lu-PSMA-617 (177Lu-vipivotide

Source: Journal of Nuclear Medicine

DOI: 10.2967/jnumed.123.265952

Authors: Thomas A. Hope, Emmanuel S. Antonarakis, Lisa Bodei, Jeremie Calais, Amir Iravani, Heather Jacene, Phillip J. Koo, Alicia K. Morgans, Joseph R. Osborne, Scott T. Tagawa, Mary-Ellen Taplin, Oliver Sartor, Michael J. Morris

Institutions: University of California, San Francisco, Masonic Cancer Center, Memorial Sloan Kettering Cancer Center, University of California, Los Angeles, University of Washington, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Dana-Farber Brigham Cancer Center, Banner MD Anderson Cancer Center, Weill Cornell Medicine, Mayo Clinic

Language: English

Topic: Radiopharmaceutical Chemistry and Applications

Subfield: Radiology, Nuclear Medicine and Imaging

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4379878996

FWCI: 7.452

Cites: 30

Cited by: 45

Related to: 10